Mesoblast stock falls 3.96 percent after FDA assay approval

Mesoblast stock fell 3.96 percent to USD 15.29 on Nasdaq on September 23, 2026, leaving the biotechnology company valued at USD 1.983 billion. The decline came as Mesoblast announced FDA approval for a new commercial potency assay covering Ryoncil lots.

FDA assay supports Ryoncil rollout

According to the September 24, 2026 release carried by AktienCheck, the FDA approved Mesoblast's T-cell Proliferation Inhibition BioAssay for release and stability monitoring of new commercial Ryoncil product lots.

The assay adds a manufacturing control rather than a new indication. Its role is to detect potency changes when production processes or facilities change, which gives the commercial product launch a more defined quality framework.

Revenue jumps in fiscal 2026

Mesoblast's financial transition is visible in the fiscal year ended June 30, 2026. According to the company's results release carried by StockTitan, total revenue rose to USD 120.25 million from USD 17.20 million in FY2025, while Ryoncil generated USD 115.20 million in net product sales.

The loss profile also improved, although profitability has not arrived. Net loss narrowed to USD 57.50 million in FY2026 from USD 102.14 million a year earlier, and operating cash outflow declined to USD 43.83 million from USD 49.95 million.

Stock remains below yearly high

At USD 15.29 on September 23, 2026, Mesoblast stock was USD 6.21 below its 52-week high of USD 21.50 and USD 2.24 above its 52-week low of USD 13.05. The market is therefore weighing a sharply improved commercial revenue base against continued losses and development spending.

The Nasdaq reference price and the September 23 daily change provide the immediate market measure. The FDA assay decision adds an operational milestone, while the FY2026 figures show that Ryoncil sales have become the central financial driver.

Mesoblast stock facts

More news and analyses on Mesoblast stock